Меню
Идёт набор NCT06190210

Predictive Value of Neurovascular Coupling in Infants With COngenital Heart Disease

Наблюдательное Congenital Heart Disease Neurodevelopmental Disorders Electroencephalography Near-Infrared Spectroscopy

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: electroencephalography, Near-Infrared Spectroscopy, neuronal cell-free DNA.
Кому может быть актуально
Состояния в реестре: Congenital Heart Disease, Neurodevelopmental Disorders, Electroencephalography, Near-Infrared Spectroscopy. Базовые параметры: до 6 мес. · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Бельгия
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

The Impact of Perioperative Neurovascular Coupling on Outcome in Infants With Congenital Heart Disease.

Обзор

Infants with congenital heart disease (CHD) are at increased risk for delayed neurodevelopment. Multiple etiological explanations have been proposed, as there seems to be a multifactorial interplay of both prenatal and perioperative factors. The main goal of this research project is to focus on peri-operative physiological risk factors in infants with CHD which impair functional brain maturation or elicit brain injury, and subsequently creating a risk model and guidelines for standardized developmental follow-up in this population. PART 1: investigation of cerebral autoregulation and neurovascular coupling The homeostasis in cerebral blood supply regardless of perfusion pressure, is called Cerebral autoregulation (CAR). Neurovascular coupling (NVC) is the phenomenon in which blood supply increases as a result of increased brain activity in a specific area. At different times in the perioperative phase, these regulatory mechanisms will be estimated based on Electroencephalography (EEG) and Near Infrared Spectroscopy (NIRS), in addition to hemodynamic parameters. PART 2: cell-free DNA (cfDNA) extraction. Non-invasive monitoring of neuronal degeneration can be performed using cfDNA extraction techniques. Serial measurements of neuronal cfDNA will be used to determine whether and when this neuronal damage has occurred. PART 3: Prognosis and outcome. These risk factors, supplemented with demographic factors and medications administered, will be combined in an Artificial Intelligence-driven model, thus establishing a risk model for neurodevelopmental outcome. This model will be compared to the current standard-of-care, both structural imaging (ultrasound and MRI) and a clinical developmental assessment at 9 and 24 months of age (Bayley Scales of Infant Development-III).

Вмешательства

  • Диагностический тест electroencephalography
    Pre-, per- and postoperative electroencephalography
  • Диагностический тест Near-Infrared Spectroscopy
    Pre-, Per- and Postoperative near-infrared spectroscopy returning regional cerebral oxygen saturation
  • Диагностический тест neuronal cell-free DNA
    CfDNA which is characterized based on methylation patterns to determine the tissue of origin

Первичные конечные точки

  • Clinical neurological development measured with Bayley Scale of Infant Development [Срок оценки: 9 months, 24 months]
  • Brain MRI structural brain abnormalities [Срок оценки: +- 1 week postoperative]

Критерии участия

Критерии включения

  • CHD warranting a first percutaneous or surgical intervention in the first 6 months, including but not limited to transposition of the great arteries (TGA), univentricular heart (UVH), Tetralogy of Fallot (TOF), coarctation of the aorta (CoA), total abnormal pulmonary venous drainage (TAPVU), Common arterial trunc (TA), large patent ductus arteriosus (PDA) or VSD and AVSD for which treatment is necessary within the first 6 months of life.
  • Treatment provided at the University Hospitals Leuven.

Критерии исключения

  • Syndromes or proven genetic conditions which are associated with neurological impairment
  • CHD warranting treatment after 6 months of life
  • Suspected or proven metabolic diseases
  • No parental/guardian consent

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

Бельгия · 1 центр
  • UZ Leuven — Leuven

Идентификаторы

NCT: NCT06190210 · S68131

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗